# Imatinib in Patients With Desmoid Tumor and Chondrosarcoma

> **NCT00928525** · PHASE2 · COMPLETED · sponsor: **Italian Sarcoma Group** · enrollment: 35 (actual)

## Conditions studied

- Advanced Desmoid Tumor
- Advanced Chondrosarcoma

## Interventions

- **DRUG:** Imatinib Mesylate

## Key facts

- **NCT ID:** NCT00928525
- **Lead sponsor:** Italian Sarcoma Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2023-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00928525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00928525, "Imatinib in Patients With Desmoid Tumor and Chondrosarcoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00928525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*